Market Research Logo

Familial Adenomatous Polyposis - Pipeline Review, H2 2018

Familial Adenomatous Polyposis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2018, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.

Familial adenomatous polyposis  (FAP) or classic FAP is a genetic condition that causes extra tissue (polyps) to form in large intestine and rectum. It is caused by germline mutations in the APC gene. Symptoms include blood or mucus in the stools, diarrhea or constipation, weight loss due to unknown reason and abdominal pain. Treatment includes surgery and medications (NSAIDs).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 2, 4, 1 and 1 respectively.

Familial Adenomatous Polyposis (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Familial Adenomatous Polyposis (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Familial Adenomatous Polyposis (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Familial Adenomatous Polyposis (Genetic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Familial Adenomatous Polyposis (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Familial Adenomatous Polyposis (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Familial Adenomatous Polyposis - Overview
Familial Adenomatous Polyposis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Familial Adenomatous Polyposis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Familial Adenomatous Polyposis - Companies Involved in Therapeutics Development
Cancer Prevention Pharmaceuticals Inc
Cellix Bio Pvt Ltd
Marina Biotech Inc
Thetis Pharmaceuticals LLC
Familial Adenomatous Polyposis - Drug Profiles
(celecoxib + lisinopril) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(eflornithine hydrochloride + sulindac) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLX-157 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FAPXIL - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy for Familial Adenomatous Polyposis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosapent ethyl - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pyrvinium pamoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RMX-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-252 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Familial Adenomatous Polyposis - Dormant Projects
Familial Adenomatous Polyposis - Discontinued Products
Familial Adenomatous Polyposis - Product Development Milestones
Featured News & Press Releases
Feb 22, 2018: Cancer Prevention Pharmaceuticals Appoints Willene Brondum Associate Vice President of Regulatory Affairs and Quality Assurance
Nov 21, 2017: Cancer Prevention Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
Sep 18, 2017: FDA Grants “Fast Track” Status to Cancer Prevention Pharmaceuticals’ Lead Drug CPP-1X/sul for Treatment of Familial Adenomatous Polyposis
Jun 12, 2017: Independent Data Monitoring Committee Recommends Continuation of Cancer Prevention Pharmaceuticals’ Phase 3 Trial for Familial Adenomatous Polyposis Patients
Mar 29, 2017: Marina Biotech to Present Data on IT-102 at 2017 American Association for Cancer Research Annual Meeting
Apr 14, 2016: Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis
Apr 04, 2016: Cancer Prevention Pharmaceuticals Completes Target Enrollment in Pivotal Phase 3 Clinical Trial Evaluating CPP-1X/sulindac in Patients with Familial Adenomatous Polyposis
Jan 27, 2016: Thetis Pharmaceuticals Awarded Key Patent for TP-252
Jan 19, 2016: Thetis Receives Orphan Drug Designation for TP-252 in Familial Adenomatous Polyposis
Oct 15, 2015: Thetis Pharmaceuticals Presents at BIO Investor Forum in San Francisco
Aug 04, 2015: Thetis Receives Notice of Allowance for Patent Covering Pharmaceutical Composition of Novel Mineral Amino Acid Derivative TP-252
Dec 05, 2013: Phase III Familial Adenomatous Polyposis Trial Now Open for Enrollment
Dec 08, 2011: S.L.A. Pharma Announces Plans For Alfa Phase III Orphan Drug Program For Familial Adenomatous Polyposis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018
Familial Adenomatous Polyposis - Pipeline by Cellix Bio Pvt Ltd, H2 2018
Familial Adenomatous Polyposis - Pipeline by Marina Biotech Inc, H2 2018
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H2 2018
Familial Adenomatous Polyposis - Dormant Projects, H2 2018
Familial Adenomatous Polyposis - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Familial Adenomatous Polyposis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report